
Opinion|Videos|March 13, 2025
The Future of RAD-ENZ Combination Therapy
Panelists discuss how regulatory approval of the radium-223 and enzalutamide combination would likely lead to significant guideline updates, particularly in treatment sequencing recommendations for patients with metastatic castration-resistant prostate cancer (mCRPC) with bone-predominant disease and adequate bone marrow function.
Advertisement
Video Player is loading.
Episodes in this series

Video content above is prompted by the following:
- Let’s say RAD-ENZ combination treatment receives regulatory approval. Do you foresee any implications for any upcoming guidelines?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Trial launches of neuromodulation therapy for erectile dysfunction after radical prostatectomy
2
Andrea B. Apolo, MD, discusses survival gains with EV/pembrolizumab in bladder cancer
3
Rectal diazepam eases instillation of nadofaragene firadenovec in NMIBC
4
Published data show benefit of niraparib with AAP in HRR-deficient mCSPC
5